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Abstract
Immunostimulatory agonists such as anti-CD137 and interleukin-2 (IL-2) have elicited potent anti-
tumor immune responses in preclinical studies, but their clinical use is limited by inflammatory
toxicities that result upon systemic administration. We hypothesized that by rigorously restricting
the biodistribution of immunotherapeutic agents to a locally accessible lesion and draining lymph
node(s), effective local and systemic anti-tumor immunity could be achieved in the absence of
systemic toxicity. We anchored anti-CD137 and an engineered IL-2Fc fusion protein to the
surfaces of PEGylated liposomes, whose physical size permitted dissemination in the tumor
parenchyma and tumor-draining lymph nodes but blocked entry into the systemic circulation
following intratumoral injection. In the B16F10 melanoma model, intratumoral liposome-coupled
anti-CD137 + IL-2Fc therapy cured a majority of established primary tumors, while avoiding the
lethal inflammatory toxicities caused by equivalent intratumoral doses of soluble immunotherapy.
Immuno-liposome therapy induced protective anti-tumor memory and elicited systemic anti-tumor
immunity that significantly inhibited the growth of simultaneously-established distal tumors.
Tumor inhibition was CD8+ T-cell-dependent and was associated with increased CD8+ T-cell
infiltration in both treated and distal tumors, enhanced activation of tumor-antigen-specific T-cells
in draining lymph nodes, and a reduction in regulatory T-cells in treated tumors. These data
suggest that local nanoparticle-anchored delivery of immuno-agonists represents a promising
strategy to improve the therapeutic window and clinical applicability of highly potent but
otherwise intolerable regimens of cancer immunotherapy.
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Introduction
Immunostimulatory antibodies and cytokines elicit potent anti-tumor immunity in a variety
of tumor models, often via the activation of cytotoxic T-lymphocyte (CTL) and natural killer
(NK) cell responses. Interleukin-2 (IL-2) stimulates the proliferation and effector functions
of both CTLs and NK cells, and has been approved for the treatment of advanced metastatic
melanoma and renal cell carcinoma (1–3). Similarly, agonistic antibodies against the
costimulatory receptor CD137 (4-1BB) expressed on the surface of activated T-cells, NK
cells, and dendritic cells, potently inhibit tumor progression in preclinical mouse models and
have begun testing in clinical trials (4–10). The priming of a CTL-mediated immune
response is particularly attractive as it has the potential to target and eradicate recurrences or
metastases in a tumor-specific manner (11–14). Nevertheless, the clinical use of
immunomodulatory agonists has been hindered by dose-limiting inflammatory toxicities that
often accompany systemic administration (15, 16). Intravenous anti-CD137 elicits liver
inflammatory damage, systemic inflammatory cytokine release, hematologic abnormalities,
and disruptions in lymphocyte trafficking (4, 17, 18), while IL-2 therapy is accompanied by
potentially lethal side effects such as capillary leak syndrome (19, 20). Although local
injections may reduce the systemic exposure to potent immuno-agonists (21–24), such
approaches remain inherently dose-limited, as soluble proteins rapidly reach the systemic
circulation following intra- or peri-tumoral injection, via lymphatic drainage or direct entry
into leaky tumor vasculature (25–30).
We recently developed a strategy to block systemic side effects from anti-CD40 and CpG
oligonucleotides, two potent anti-tumor therapeutics, by locally administering these
immuno-agonists conjugated to liposomal nanoparticles (25). Intratumorally (i.t.)-injected
anti-CD40/CpG-liposomes dispersed throughout the tumor matrix and entered local
lymphatics but were restricted from penetrating tumor vasculature or reaching the systemic
circulation, thus prolonging the local immunotherapy exposure while eliminating symptoms
of liver toxicity and systemic cytokine storms observed following soluble i.t. therapy.
Although i.t. anti-CD40/CpG-liposomes delayed the progression of established tumors in the
poorly immunogenic B16F10 melanoma model (25), this treatment combination failed to
induce complete/durable tumor rejections. We hypothesized that anti-CD137 and IL-2 co-
delivered via this liposome-anchored approach would synergistically activate tumor-specific
T-lymphocytes in the tumor and tumor-draining lymph nodes (TDLNs), thereby priming
effective local immune responses and the systemic dissemination of CTLs capable of
targeting distal untreated lesions (31, 32).
Using the murine B16F10 model, we show here that local therapy with anti-CD137-
liposomes and IL-2-liposomes leads to potent anti-tumor activity with no evidence for
systemic toxicity, unlike i.t. soluble anti-CD137+IL-2 treatment. Importantly, control of
local tumor progression by i.t. liposome therapy was accompanied by systemic anti-tumor
immune responses, which restrained the growth of simultaneously established distant
tumors. Thus, liposomal delivery enables aggressive local treatment with high doses of
immunotherapeutic agents, promoting a systemic immune response without systemic
toxicity.
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Materials and Methods
Materials
Anti-CD137 (clone LOB12.3), anti-CD8a (clone 2.43), anti-NK1.1 (clone PK136), and rat
IgG isotype control antibodies were from BioXCell (West Lebanon, NH).
Dioleoylphosphocholine (DOPC), polyethylene glycol (PEG)2000-
distearoylphosphoethanolamine (DSPE), maleimide-PEG2000-DSPE (Avanti Polar Lipids,
Alabaster, AL), and lipid tracer DiD (Invitrogen, Grand Island, NY) were used as received.
Fluorescent antibodies against mouse CD45, CD3, CD8a, CD4, NK1.1, Thy1.1, IFN-γ, and
Foxp3 were from eBioscience (San Diego, CA). The Cytometric Bead Array Mouse
Inflammation Kit was from BD Biosciences (San Jose, CA).
Preparation of anti-CD137-liposomes and IL-2Fc-liposomes
IL-2Fc was prepared as a bivalent fusion of the N-terminus of murine IL-2 to the heavy
chain of murine IgG2a (Fig. 1A, Gai and Wittrup, manuscript in preparation) and expressed
in HEK293 Freestyle cells (Invitrogen). Anti-CD137-coupled liposomes (Lip-αCD137) and
IL-2Fc-coupled liposomes (Lip-IL-2Fc) were prepared as previously described (25): briefly,
liposomes were first prepared with a composition of cholesterol/DOPC/PEG-DSPE/
maleimide-PEG-DSPE at 35/60/2.5/2.5 or 35/62.5/0/2.5 mol% for Lip-αCD137 or Lip-
IL-2Fc, respectively, and with 0.1 mol% of the fluorescent dye DiD for labeling. Anti-
CD137 and IL-2Fc were treated with 1.8mM dithiothreitol to expose hinge region thiols,
then mixed with liposomes for covalent maleimide-thiol conjugation. Conjugated liposomes
were washed with PBS to remove unbound protein. The quantification of liposome-bound
anti-CD137 or IL-2Fc was performed by ELISA following solubilization of liposomes in
0.5% Tween 20 buffer. Endotoxin levels in Lip-αCD137 and Lip-IL-2Fc were found to be
<1 EU/mg of liposomes by LAL assay (Pierce, Rockford, IL).
In vitro bioactivity of Lip-αCD137 and Lip-IL-2Fc
C57Bl/6 splenocytes were polyclonally activated for 2 days, CFSE-labeled, then re-plated
with 20 ng/ml IL-2 (Peprotech), IL-2Fc, or Lip-IL-2Fc (equivalent molar doses). Specific
binding of fluorescent IL-2Fc-liposomes to T-cells was assessed by flow cytometry after 2h,
while total live cell counts and CFSE dilution were analyzed after 48h. In parallel, activated
splenocytes were cultured with IL-2 for days 2–4, followed by 5 μg/ml soluble anti-CD137
or Lip-αCD137. Binding of fluorescent anti-CD137-liposomes was analyzed after 2h, and
culture supernatants were collected after 24h for the measurement of IFN-γ by ELISA.
In vivo tumor therapy
Mice were handled in the USDA-inspected MIT Animal Facility following federal, state,
and local guidelines. 6–8 week-old female C57Bl/6 mice (Jackson Laboratory, Bar Harbor,
ME) were inoculated subcutaneously with 5×104 B16F10 cells (authenticated from
American Type Culture Collection, cultured <6 months before use) on a single flank or both
hind flanks. Tumor area was calculated as the product of 2 measured orthogonal diameters
(D1×D2). Mice were treated on one flank with intra-tumoral injections on days 9/12/16
unless otherwise indicated, using PBS, soluble anti-CD137+IL-2Fc, Lip-αCD137+Lip-
IL-2Fc, or rat IgG isotype-liposomes (Lip-IgG), at an equivalence of 100 μg antibody + 20
μg IL-2 per dose unless otherwise indicated. For in vivo depletion, 400 μg/dose of anti-
CD8a or anti-NK1.1 were injected intraperitoneally on days 7/12/16. To assess
establishment of tumor-specific memory responses, single-tumor-bearing mice were treated
as described above, and at 4 or 8 weeks post-primary inoculation, a secondary challenge of
5×104 B16F10 cells was inoculated into the opposite hind flank and monitored without
additional therapy. Weights of treated mice were measured daily as an indicator of body
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condition and systemic toxicity. Serum levels of anti-CD137 or IL-2 were quantified by
ELISA, and serum cytokines were measured by Cytometric Bead Array (BD Biosciences).
For additional tumor models, Balb/c mice (Jackson Laboratory) or C57Bl/6 mice were
inoculated s.c. on a single flank with 2×106 A20 cells (ATCC, cultured <6 months before
use) or 3×105 TC-1 cells (authenticated and received from Dr. T.C. Wu, Johns Hopkins
University), respectively, then treated on days 7/9/11 post-inoculation with intratumoral
injections of PBS or Lip-αCD137+Lip-IL-2Fc (75 μg antibody + 15 μg IL-2 per dose).
Flow cytometry and histological analysis
Mice with B16F10 tumors on both hind flanks were injected with DiD-labeled Lip-IgG, Lip-
αCD137+Lip-IL-2Fc, or saline on one flank only. The treated and contralateral tumors,
proximal and contralateral TDLNs, and spleens were harvested and dissociated into single-
cell suspensions for flow cytometry analysis on a FACSCanto II (BD Biosciecnes).
Regulatory T-cell (Treg) levels were quantified by intracellular Foxp3 staining. For
histological analysis, treated tumors or tumor-draining lymph nodes were snap-frozen for
cryosection. Tissue sections were imaged on a Zeiss LSM 510 confocal microscope for the
presence of DiD-labeled liposomes, with or without CD3/B220 co-staining. For
pharmacokinetic analysis, treated tumors were harvested at indicated timepoints and
digested in Tissue Protein Extraction Reagent + Halt Protease Inhibitor Cocktail (Pierce);
supernatants from homogenized tisuses were then analyzed by fluorescence for DiD
concentrations and by ELISA for concentrations of anti-CD137 and IL-2Fc.
Ex vivo T-cell activation
IFN-γ production by lymphocytes was assessed by placing single-cell suspensions from
TDLNs in culture for 12h, with or without PMA (50 ng/ml) + ionomycin (1 μM) re-
stimulation, followed by addition of brefeldin A for 5h. Intracellular IFN-γ was analyzed by
flow cytometry, while ex vivo culture supernatants were analyzed by ELISA for secreted
cytokine.
Adoptive transfer of B16 tumor-specific CD8+ T-cells
Naïve CD8+ T-cells expressing a transgenic TCR specific for the B16 melanoma self-
antigen gp100 (33) were isolated from female Thy1.1+ Pmel-1 mice (Jackson Laboratory)
using a CD8 Negative Isolation Kit (Stemcell Technologies, Vancouver, Canada), CFSE-
labeled, then adoptively transferred (2×106 cells/mouse) into B16F10 tumor-bearing mice
on day 7 post-tumor inoculation. Mice were treated with i.t. liposome therapy as previously
described, and the treated and contralateral TDLNs were excised on day 14 for flow
cytometry analysis of CFSE dilution in CD8+Thy1.1+ Pmel cells.
Statistical analysis
Data are shown as mean ± SEM. Average tumor growths were compared using two-way
ANOVA, and Kaplan-Meier survival curves were compared by log-rank test. For all other
data, comparisons of two experimental groups were analyzed by two-tailed unpaired t-tests.
Statistical analysis was performed using GraphPad Prism software.
Results
Liposome-anchored anti-CD137 and IL-2Fc retain potent bioactivity
We first prepared liposome-anchored immunotherapeutics by conjugation of monoclonal
anti-CD137 or an engineered murine IL-2Fc fusion protein (Gai and Wittrup, manuscript in
preparation) to the surfaces of PEGylated liposomes (Fig. 1A). Reduced disulfides of the Fc
hinge region were linked to maleimide-terminated phospholipids on the liposomes, yielding
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130±10 μg of conjugated anti-CD137 or 53±7 μg of conjugated IL-2 (cytokine equivalence)
per mg liposomes. Anti-CD137-coupled liposomes (Lip-αCD137) and IL-2Fc-coupled
liposomes (Lip-IL-2Fc) were then size-extruded by membrane filtration to a mean diameter
of 160±10 nm prior to use. Liposome-anchored IL-2Fc and αCD137 demonstrated specific
binding to activated murine CD4+ and CD8+ T-cells in vitro (Fig. 1B), and retained T-cell
stimulatory activity: CD4+ and CD8+ T-cells showed similar levels of proliferation in
response to equivalent doses of soluble IL-2, soluble IL-2Fc, or Lip-IL-2Fc (Fig. 1C), while
Lip-αCD137 was ~6-fold more potent than soluble αCD137 in inducing IFN-γ secretion
from activated T-cells (Fig. 1D).
Intratumorally-injected Lip-αCD137+Lip-IL-2Fc therapy is locally retained and minimizes
systemic exposure, preventing lethal systemic inflammatory toxicity
Since anti-CD137 and IL-2 elicit significant inflammatory toxicity upon systemic
administration (17–19), we examined whether nanoparticle anchoring would enable local
retention of these agents without systemic dissemination following intratumoral injections,
in order to minimize systemic toxicity. Subcutaneous B16F10 tumors were injected i.t. with
fluorescently-labeled Lip-αCD137 (100 μg antibody) and Lip-IL-2Fc (20 μg IL-2), on day
10 post-tumor inoculation. Fig. 2A shows representative histology 24h after injection,
demonstrating the presence of liposomes throughout the tumor. Fluorescence measurements
from homogenized tumor tissues showed that liposomes persisted at the treated tumor for
~96h post-injection (Supplementary Fig. S1A), while anti-CD137 and IL-2 were detectable
up to 48h post-liposome injection (Supplementary Fig. S1B). Histological sections of
TDLNs taken at 24h post-injection showed liposome accumulation primarily in the
subcapsular sinuses, consistent with direct lymphatic drainage (Fig. 2B and Supplementary
Fig. S2).
In parallel, we measured serum levels of αCD137 and IL-2Fc 18h following a single i.t.
dose of either liposome-coupled or soluble therapy. In contrast to soluble anti-
CD137+IL-2Fc, i.t. liposome therapy resulted in minimal detectable levels of either agonist
in the blood (Fig. 2C–D), confirming the ability of immuno-liposomes to physically restrict
these locally-injected therapeutics. Flow cytometry analysis on day 14 following i.t.
treatment of B16F10 tumors on days 9 and 12 showed that ~65% of tumor-infiltrating CD8+
T-cells and NK cells were labeled with immuno-liposomes, while isotype control liposomes
(Lip-IgG) showed substantially lower nonspecific binding (Fig. 2E). Immuno-liposomes
also bound to 5–15% of CD8+ T-cells in the proximal TDLNs, but were not detectable in
spleens or distal LNs following intratumoral injections (Fig. 2F), confirming that lymphatic
drainage of liposomes was confined to the treatment-proximal LN.
We next tested whether the dramatic reduction in systemic exposure achieved by liposome-
anchored delivery impacted the systemic toxicity of αCD137+IL-2Fc therapy. Soluble i.t.
doses of αCD137+IL-2Fc (days 9/12/16) induced significant elevations in serum levels of
inflammatory cytokines (Fig. 3A) and rapid weight loss (Fig. 3B), accompanied by
shivering, sluggish mobility, and other symptoms consistent with the measured systemic
cytokine storm; these side effects were fatal in 2/8 soluble-treated animals (Fig. 3B). Mice
treated with half-doses of soluble therapy (50 μg αCD137 + 10 μg IL-2Fc per dose)
experienced comparable weight loss and fever-like symptoms, although without lethality
(Fig. 3B). In contrast, full doses of i.t. Lip-αCD137+Lip-IL-2Fc elicited only minimal
increases in systemic cytokines compared to PBS-treated mice, at either 1, 2, 3, or 5 days
after the start of therapy (Fig. 3A and data not shown). Furthermore, i.t. liposome-treated
mice did not exhibit weight loss or other physiologic symptoms of systemic cytokine release
(Fig. 3B). Interestingly, intravenous administration of Lip-αCD137+Lip-IL-2Fc induced
intermediate systemic inflammation (Supplementary Fig. S3), indicating that liposome-
mediated elimination of toxicity was dependent on the restricted biodistribution of
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liposomes at the treated tumor and TDLNs. Thus, local liposome treatment enabled the safe
administration of an otherwise intolerable dose of this immunostimulatory therapy.
Intratumoral immuno-liposome therapy regresses primary tumors and induces protective
anti-tumor memory
To test the anti-tumor efficacy of immuno-liposomes versus systemically-disseminating
soluble therapy, C57Bl/6 mice bearing s.c. B16F10 tumors were given i.t. injections of PBS,
control Lip-IgG, Lip-αCD137+Lip-IL-2Fc (100 μg αCD137 + 20 μg IL-2 per injection), or
a non-lethal dose of i.t. soluble therapy (50 μg αCD137 + 10 μg IL-2 per injection). Soluble
and liposome-coupled immunotherapy elicited potent anti-tumor immunity, inducing
complete tumor regressions in 60–70% of treated mice (with undetectable recurrence for at
least 50 days) and substantially delaying tumor progression in all remaining animals (Fig.
4A). However, only immuno-liposome therapy was able to achieve this therapeutic efficacy
in the absence of systemic toxicity (Fig. 3). Combination therapy maximized the efficacy of
these agents, as mice treated with Lip-αCD137 or Lip-IL-2Fc alone induced only modest
inhibition of tumor growth compared to PBS-treated controls (Supplementary Fig. S4). We
also assessed the anti-tumor efficacy of i.t. Lip-αCD137+Lip-IL-2Fc against s.c. A20
lymphoma tumors in Balb/c mice, and s.c. TC-1 tumors expressing the HPV-16 E7 cervical
cancer antigen in C57Bl/6 mice. As shown in Supplementary Fig. S5, liposome therapy
eliminated tumors in 100% of A20 tumor-bearing mice, and growth of TC-1 tumors was
also significantly inhibited. Thus i.t. Lip-αCD137+Lip-IL-2Fc therapy was effective across
multiple tumor models and murine genetic backgrounds.
To test whether Lip-αCD137+Lip-IL-2Fc therapy established tumor-specific immunological
memory, B16F10 tumor-bearing mice were treated as above, and then challenged 27 days
post-primary inoculation with a secondary challenge of 5×104 B16F10 cells on the distal
flank. All liposome-treated animals and 7/8 soluble-treated animals rejected the secondary
challenge (irrespective of whether the primary tumor had been completely cured), while
control naïve animals or mice bearing PBS-treated primary tumors all showed rapid tumor
outgrowth (Fig. 4B). An additional distal tumor challenge on day 55, performed on a subset
of previously liposome-treated animals, was again completely rejected while untreated
animals showed rapid tumor progression (data not shown).
Local immuno-liposome therapy induces systemic anti-tumor immunity against untreated
distal tumors
To determine whether localized immuno-liposome therapy initiated a systemic anti-tumor
immune response capable of targeting distal tumors, mice were inoculated with B16F10
cells s.c. on both hind flanks simultaneously and treated with i.t. liposomes in one flank.
Treated tumors were either completely cured (89%) or showed significantly delayed
progression (Fig. 5A), while contralateral untreated tumors were also strongly inhibited (Fig.
5A–B), with 22% of dual-tumor-bearing animals achieving rejection of the distal
simultaneously-established tumor (Fig. 5B). A prolonged treatment regimen did not further
enhance the inhibition of distal untreated tumors, although i.t.-treated tumors that had
escaped the initial anti-tumor response could be arrested by extended therapy
(Supplementary Fig. S6). Importantly, no symptoms of inflammatory toxicity were detected
during the sustained schedule of immunotherapy, indicating that localized immuno-liposome
treatment allows for a broad therapeutic window. Systemic (intraperitoneal) injections of
low-dose soluble anti-CD137 (10 μg) + IL-2Fc (2 μg) showed no therapeutic effect against
subcutaneous tumors (data not shown), suggesting that distal tumor inhibition following
immuno-liposome therapy was mediated by a disseminated immune response, and not by
low levels of immunotherapeutic agents leaking to the distal site.
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We next assessed the relative importance of CD8+ T-cells and NK cells in anti-tumor
responses elicited by Lip-αCD137+Lip-IL-2Fc. In the dual-tumor B16F10 model, CD8+
depletion almost completely abrogated the efficacy of immuno-liposome therapy (Fig. 6A),
and the survival of liposome-treated CD8-depleted mice was not statistically different from
untreated animals (Fig. 6B). In contrast, no loss in efficacy was detected in NK cell-depleted
liposome-treated mice (Fig. 6A–B). Thus, although immuno-liposomes bound to both CTLs
and NK cells in treated tumors and tumor-proximal LNs (Fig. 2E–F), only CTLs were
required for protective immunity in this model.
Lip-αCD137+Lip-IL-2Fc therapy induces an immuno-activated milieu at tumors and tumor-
draining LNs
To evaluate immunological changes in the tumor microenvironment following i.t. Lip-
αCD137+Lip-IL-2Fc therapy, we quantified the levels of tumor-infiltrating CTLs and
regulatory T-cells (Treg) in B16F10 dual-tumor-bearing mice. In untreated or Lip-IgG-
treated tumors, low levels of CTLs were detected at day 15, similar to pre-treatment levels
on day 9 (Fig. 7A), while CD45+CD4+Foxp3+ Treg became prevalent by day 15 (Fig. 7B),
characteristic of an immunosuppressive tumor microenvironment (34–36). In contrast, we
observed a ~21-fold increase in CTLs within immuno-liposome-treated tumors by day 15
(Fig. 7A), as well as significantly increased levels of CTLs in the contralateral tumors (Fig.
7A), despite the absence of detectable liposomes in the distal tumor (data not shown). Treg
accumulation was also blocked in tumors treated with i.t. Lip-αCD137+Lip-IL-2Fc, though
not in the contralateral tumors of these mice (Fig. 7B). Calculated CTL:Treg ratios thus
showed a substantial shift in immune activation within both treated and contralateral tumors
in liposome-treated mice compared to untreated controls (Fig. 7C). NK cell levels were
unaffected in treated or contralateral tumors following immuno-liposome therapy
(Supplementary Fig. S7), consistent with the lack of impact of NK cell depletion.
Since immuno-liposomes also access T-cells in the TDLN (Fig. 2B, F), we evaluated
whether LN-resident T-cells were primed following liposome therapy, by analyzing IFN-γ
production in response to ex vivo re-stimulation. We found increased numbers of IFN-γ-
producing CD8+ and CD4+ T-cells in both treated and contralateral TDLNs of dual-tumor-
bearing mice on day 14 compared to untreated controls (Fig. 7D–E), demonstrating an
impact on immune responses in distal nodes despite the absence of direct liposome
stimulation at those LNs (Fig. 2F). Re-stimulated lymphocytes from the proximal draining
LNs of liposome-treated mice also secreted ~5-fold more IFN-γ compared to lymphocytes
from untreated mice, signifying greater per-cell secretion in addition to the increased
frequency of IFN-γ-producing cells (Fig. 7F).
To gain further insight into how i.t. immuno-liposome therapy mediated a systemic anti-
tumor response, we examined the de novo priming of tumor-specific T-cells in tumor-
draining LNs. CFSE-labeled, naïve Pmel-1 CD8+ T-cells, which express a transgenic TCR
specific for the B16 self-antigen gp100 (32), were adoptively transferred into dual-tumor-
bearing mice prior to immuno-liposome therapy in one tumor only. At day 14, a basal level
of Pmel proliferation was observed in the LNs of untreated tumor-bearing mice (Fig. 7G–H).
However, Pmel cells recovered from the treatment-proximal and contralateral LNs of
immuno-liposome-treated mice trended towards a greater number of divisions (Fig. 7G–H),
consistent with the therapeutic activation of endogenous LN-resident CTLs described above
(Fig. 7D–F). The range of proliferative responses observed at the treatment-proximal LNs
may reflect the variability in tumor burden reduction at this timepoint. Interestingly,
transferred Pmel cells were not detected on day 14 in either treated or contralateral tumors,
nor in control untreated tumors (data not shown), indicating that tumor-specific CTLs
activated at the LNs of liposome-treated mice had not yet trafficked to tumor lesions. This
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suggests that the early inhibition of distal tumor growth was mediated by the dissemination
of stimulated CTLs originating from the treated tumor.
Discussion
Previous studies have established the anti-tumor efficacy of anti-CD137 and IL-2,
particularly as a combination therapy (31, 37–42). However, significant inflammatory
toxicities have been observed in preclinical and clinical studies of both agents (4, 8, 17–19),
limiting the dosages that can be tolerated in patients. Here we show that liposome
conjugation enables intratumoral administration of a highly efficacious regimen of anti-
CD137 + IL-2 therapy in the complete absence of the severe systemic toxicities elicited by
systemic or local administration of equivalent soluble doses. In addition to complete
regression of a majority of locally-treated tumors, Lip-αCD137+Lip-IL-2Fc primed
systemic immunity that inhibited established distal tumors and rejected secondary tumor
inoculations after the cessation of therapy. The increased frequency of CTLs within both
treated and distal untreated tumors following Lip-αCD137+Lip-IL-2Fc therapy, the loss of
efficacy in CD8-depleted mice, and the increased number of activated IFN-γ-producing
CTLs in proximal and contralateral TDLNs all provided evidence for combined local and
systemic CTL-mediated anti-tumor immunity.
Preclinical studies of intratumorally-administered soluble immunotherapies have shown
reduced systemic side effects by decreasing the dosages required for tumor inhibition, while
eliciting both local and systemic tumor regression (11, 12, 21, 22, 43). Similar findings were
recently reported by Levy and colleagues in a phase I/II study of local CpG injection
combined with local radiation therapy (23, 44). Additionally, Fransen et al. (22) showed that
low doses of anti-CD40 can be locally injected without toxicity by formulation in a slow-
release emulsion, although a 5-fold higher dose administered via the same formulation was
reported to cause liver inflammation. This finding highlights the fact that locally-
administered soluble antibodies or cytokines remain capable of leaking into systemic
circulation, even if delivered via controlled-release vehicles, depending on the dosage
administered (22, 26–30, 45). By contrast, the nanoparticle-anchoring strategy described
here physically restricts immuno-agonists at the local injection site even when administered
repeatedly at high doses, while retaining efficacious local and systemic anti-tumor
immunity.
Combined Lip-αCD137+Lip-IL-2Fc therapy exhibited much greater efficacy than
monotherapy with either agent alone. Preliminary data from our laboratory has shown that
i.t. IL-2 therapy induces the upregulation of CD137 receptor expression on tumor-infiltrating
CD8+ T-cells (BK and DJI, unpublished observations), analogous to observations by
Redmond et al. (40) describing IL-2R-regulated increases in OX40 expression on CTLs.
Palazon et al. (21) also recently demonstrated that hypoxia induces CD137 expression in
tumor-infiltrating T-cells, allowing intratumoral αCD137 therapy to mediate local and distal
tumor inhibition. Paradoxically, CD137 agonists alone or in combination with IL-2 have
been shown to stimulate Treg cell expansion in vivo and in vitro (5, 46, 47), indicating a
potential role in treating autoimmune conditions. Although we confirmed that combined
Lip-αCD137+Lip-IL-2Fc induced moderate proliferation of sorted CD4+CD25+Foxp3+
Tregs in vitro (data not shown), i.t. Lip-αCD137+Lip-IL-2Fc therapy clearly blocked Treg
accumulation within treated tumors and significantly enhanced tumor-infiltrating CTL:Treg
ratios, a measure known to correlate with favorable anti-tumor immunity (48). Furthermore,
immuno-liposome therapy stimulated IFN-γ production in CD4+ T-cells as well as CD8+ T-
cells in the proximal TDLNs, indicating the activation of effector CD4+ T-cells.
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Following liposome therapy, the growth of distal untreated tumors was significantly
inhibited, correlating with an increased density of tumor-infiltrating CTLs. The absence of
liposome accumulation at distal tumors and LNs, the negligible levels of systemic
inflammatory cytokines/chemokines following immuno-liposome therapy, and the lack of
Pmel T-cell infiltration into tumors after 1 week together suggested that these increased CTL
levels did not result from de novo naïve T-cell priming at the TDLNs. Rather, immuno-
liposome therapy may have re-activated existing effector T-cells in the i.t.-treated tumor/
TDLNs, which rapidly disseminated systemically to enact distal tumor inhibition, a
phenomenon previously described by Straten et al (49). This model remains consistent with
the lack of detectable liposomes in the contralateral tumor if the disseminated T-cells were
indirectly stimulated in the i.t.-treated site (and thus not directly labeled) or if liposomes
were degraded during lymphocyte trafficking.
In conclusion, nanoparticle-mediated “anchoring” of immunotherapy biologics is a versatile
strategy for priming anti-tumor immunity. By localizing the biodistribution of therapy,
highly potent but previously intolerable immunotherapeutic regimens can be administered at
large doses within an accessible lesion, for the induction of systemic anti-tumor immunity
without detectable systemic inflammation. In addition, this approach may be synergistic in
combination with the administration of better-tolerated immunotherapy agents such as anti-
CTLA-4 or anti-PD-1 that are known to promote tumor regression in humans (50).
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Figure 1.
Anti-CD137-liposomes (Lip-αCD137) and IL-2Fc-liposomes (Lip-IL-2Fc) are bioactive for
T-cell binding and stimulation in vitro. A. Schematic of immuno-liposome preparation. B.
Flow cytometry histograms of activated CD4+ and CD8+ T-cells after 2h of incubation in
vitro with fluorescently-labeled Lip-IL-2Fc or Lip-αCD137 (solid unfilled), unconjugated
liposomes (dashed unfilled), or no liposomes (grey filled). C. In vitro T-cell proliferation
after 48h incubation with Lip-IL-2Fc, IL-2Fc, or IL-2 as measured by cell counts
(normalized to unstimulated cells) or CFSE dilution. *p=0.002, **p<0.0001. D. IFN-γ
production by polyclonal T-cells stimulated by Lip-αCD137, isotype control liposomes, or
soluble anti-CD137 after 24h. *p=0.0002, **p<0.0001.
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Figure 2.
Anti-CD137 and IL-2Fc immuno-liposomes are locally confined following intratumoral
administration, minimizing systemic exposure. Established s.c. B16F10 tumors were
injected i.t. with PBS, soluble anti-CD137 (100 μg) + IL-2Fc (20 μg IL-2), or equivalent
doses of Lip-αCD137+Lip-IL-2Fc. A–B. Representative cryosections of a B16F10 tumor
(A, dashed line indicates tumor boundary) and the TDLN (B), 24h post-injection of
fluorescently-labeled immuno-liposomes (white). Scale bars 500 μm. C–D. Serum levels of
anti-CD137 (C) and IL-2Fc (D) were analyzed 18h post-injection. *p<0.0001. E. Mice
(n=5–9) received 2 i.t. doses of control Lip-IgG or Lip-αCD137+Lip-IL-2Fc on days 9 and
12 post-tumor inoculation, and tumors were analyzed by flow cytometry on day 14 for the
percentage of DiD+ (liposome+) cells among CTLs or NK cells. *p=0.0005, **p<0.0001. F.
Mice (n=5–9) were treated i.t. as in part (E) and the proximal TDLNs, contralateral LNs,
and spleens were analyzed on day 14; *p=0.01.
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Figure 3.
Immuno-liposome delivery of anti-CD137 and IL-2Fc prevents lethal systemic
inflammatory toxicity. A. Mice (n=4) were inoculated s.c. with B16F10 cells (5×104) and
treated on day 9 with i.t. injection of soluble anti-CD137 + IL-2Fc or Lip-αCD137+Lip-
IL-2Fc (100 μg antibody, 20 μg IL-2, “full dose”). Serum cytokine levels were measured on
day 11 by Cytometric Bead Array. *p=0.003, **p=0.0003, ***p<0.0001. B. Average weight
changes in tumor-bearing mice (n=7–11) treated intratumorally on days 9/12/16 (arrows)
with saline, immuno-liposomes, or soluble αCD137+IL-2Fc (full or half-dose). Crosses
denote treatment-related fatalities in the group receiving soluble therapy at full doses.
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Figure 4.
Local immuno-liposome therapy eliminates B16F10 tumors and elicits protective anti-tumor
memory. A. Individual tumor growth curves from mice inoculated s.c. with 5×104 B16F10
tumor cells, then treated i.t. on days 9/12/16 (arrows) with PBS, control Lip-IgG, Lip-
αCD137 (100 μg) + Lip-IL-2Fc (20 μg IL-2), or the maximum tolerable dose of soluble
anti-CD137 (50 μg) + IL-2Fc (10 μg IL-2). Boxed fractions indicate long-term cures in each
group. B. Primary tumors were treated as described for part (A), followed by a secondary
inoculation of 5×104 B16F10 cells s.c. in the opposite flank on day 18 for PBS-treated mice,
or on day 27 for immuno-liposome-treated and soluble-treated mice. Naïve animals without
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primary tumors were simultaneously inoculated to validate tumor cell viability. Boxed
fractions indicate complete rejections of the secondary tumor challenge.
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Figure 5.
Local immuno-liposome therapy elicits systemic immunity that inhibits simultaneously
established distal tumors. Mice (n=9–10) were inoculated s.c. with B16F10 tumors on both
hind flanks simultaneously, then treated i.t. on one flank with PBS or Lip-αCD137+Lip-
IL-2Fc on days 9/12/16 (arrows). A. Average growths of treated tumors and contralateral
untreated tumors. *p=0.002, **p=0.009, ***p<0.0001. B. Individual growth curves of
contralateral untreated tumors in i.t. PBS-treated or immuno-liposome-treated mice. Boxed
numbers indicate fraction of long-term cures.
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Figure 6.
CD8+ T-cells are required for therapeutic efficacy of Lip-αCD137+Lip-IL-2Fc. Mice (n=6–
10) bearing B16F10 tumors on both hind flanks were injected i.p. with anti-CD8a or anti-
NK1.1 depleting antibodies (400 μg/dose) on days 7/12/16, and treated i.t. at one flank on
days 9/12/16 (arrows) with PBS or Lip-αCD137+Lip-IL-2Fc. A. Average growths of
liposome-treated tumors and contralateral untreated tumors with or without CD8/NK cell
depletion. *p=0.01, **p=0.006. B. Kaplan-Meier survival curve of dual-tumor-bearing mice
treated with PBS or Lip-αCD137+Lip-IL-2Fc therapy (arrows), with or without cell
depletion. *p=0.004, **p<0.0001.
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Figure 7.
Lip-αCD137 + Lip-IL-2Fc therapy induces immune activation at treated and distal B16F10
tumors and tumor-draining LNs. A–F. Dual-tumor-bearing mice were treated i.t. on one
flank with PBS, control Lip-IgG, or Lip-αCD137+Lip-IL-2Fc on days 9 and 12 post-
inoculation. On day 15, treated (filled symbols) and contralateral untreated (open symbols)
tumors were analyzed by flow cytometry to determine numbers of tumor-infiltrating CTLs
(A, *p=0.03, ***p=0.007), Tregs (B, **p=0.02), and CTL:Treg ratios (C, ***p=0.001). On
day 14, cells from treatment-proximal and contralateral tumor-draining LNs were cultured
ex vivo for 12h with or without PMA/ionomycin restimulation, and IFN-γ-producing CD8+
(D) and CD4+ T-cells (E) were enumerated by intracellular cytokine staining; *p=0.02,
**p<0.01, ***p<0.003. Culture supernatants were analyzed by ELISA for secreted IFN-γ
(F); *p=0.002, **p<0.001. G–H. Dual-tumor-bearing mice received an adoptive transfer of
2×106 naïve CFSE-labeled Pmel-1 CD8+ T-cells on day 7, then were treated on days 9+12
as above. CFSE dilution in Pmel-1 cells from TDLNs was analyzed on day 14 by flow
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cytometry (G), and mean division indices (mean divisions per cell) were calculated (H);
**p=0.002.
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